Over the last decade, the better understanding of immune checkpoints in cancer development, prompted the appearance of novel immunotherapy agents like programmed cell death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors which demonstrated to be surprisingly effective in the treatment of different types of cancer [26, 27]. Here, PDCD1 is linked to cancer.